• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

May 7, 2018
Company Drug/Device Medical Condition Status
Ocular Therapeutix OTX-TIC (travoprost intracameral implant) glaucoma and ocular hypertension Phase I trial initiated
Galapagos NV and MorphoSys AG MOR106 moderate-to-severe atopic dermatitis (AD) Phase II trial initiated evaluating 180 subjects
ThromboGenics NV THR-317 administered in combination with ranibizumab (Lucentis, Novartis) Diabetic Macular Edema (DME) Phase II trial initiated enrolling 70 subjects
Wize Pharma, Inc. LO2A Symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren’s syndrome Phase IV trial initiated enrolling 60 subjects in the Israel
Immusoft Corporation Immune System Programming MPS I (Mucopolysaccharidosis type I) Orphan Drug Designation granted by the FDA
Stealth Biotherapeutics elamipretide Leber’s hereditary optic neuropathy (LHON) Orphan Drug Designation granted by the FDA
Conavi TM Medical Inc. Novasight Hybrid System simultaneous imaging of coronary arteries with both intravascular ultrasound (VUS) and Optical Coherence Tomography (OCT) 510(k) clearance granted by the FDA
Jazz Pharmaceuticals Xyrem (sodium oxybate) oral solution cataplexy and Excessive Daytime Sleepiness (EDS) in pediatric narcolepsy patients sNDA filed with the FDA
Acceleron Pharma Inc. ACE-083 Facioscapulohumeral muscular dystrophy (FSHD) treatment Fast Track Designation granted by the FDA
SCYNEXIS, Inc. Oral SCY-078 vulvovaginal candidiasis (VVC) and for the prevention of recurrent VVC Fast Track Designation and Qualified Infectious Disease Product (QIDP) granted by the FDA

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing